133 related articles for article (PubMed ID: 16715392)
1. Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulations.
Patankar N; Wasan KM
Pharm Res; 2006 May; 23(5):1020-4. PubMed ID: 16715392
[TBL] [Abstract][Full Text] [Related]
2. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content.
Kennedy AL; Wasan KM
J Pharm Sci; 1999 Nov; 88(11):1149-55. PubMed ID: 10564063
[TBL] [Abstract][Full Text] [Related]
3. Differences in human phospholipid transfer protein activity following incubation of Fungizone compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma.
Henderson RJ; Leon CG; Wasan KM
Drug Dev Ind Pharm; 2009 Sep; 35(9):1139-46. PubMed ID: 19381990
[TBL] [Abstract][Full Text] [Related]
4. Unidirectional inhibition of lipid transfer protein I-mediated transfer of cholesteryl esters between high-density and low-density lipoproteins by amphotericin B lipid complex.
Sivak O; Lau B; Patankar N; Wasan KM
Pharm Res; 2004 Dec; 21(12):2336-9. PubMed ID: 15648266
[TBL] [Abstract][Full Text] [Related]
5. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
6. Differences in the method by which plasma is separated from whole blood influences amphotericin B plasma recovery and distribution following amphotericin B lipid complex incubation within whole blood.
Ramaswamy M; Wasan KM
Drug Dev Ind Pharm; 2001 Sep; 27(8):871-5. PubMed ID: 11699840
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans.
Wasan EK; Bartlett K; Gershkovich P; Sivak O; Banno B; Wong Z; Gagnon J; Gates B; Leon CG; Wasan KM
Int J Pharm; 2009 May; 372(1-2):76-84. PubMed ID: 19236839
[TBL] [Abstract][Full Text] [Related]
8. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein.
Wasan KM; Morton RE; Rosenblum MG; Lopez-Berestein G
J Pharm Sci; 1994 Jul; 83(7):1006-10. PubMed ID: 7965656
[TBL] [Abstract][Full Text] [Related]
9. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations.
Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J
Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388
[TBL] [Abstract][Full Text] [Related]
10. Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins.
Wasan KM; Brazeau GA; Keyhani A; Hayman AC; Lopez-Berestein G
Antimicrob Agents Chemother; 1993 Feb; 37(2):246-50. PubMed ID: 8452354
[TBL] [Abstract][Full Text] [Related]
11. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas.
Wasan KM; Ramaswamy M; McIntosh MP; Porter CJ; Charman WN
J Pharm Sci; 1999 Feb; 88(2):185-90. PubMed ID: 9950636
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.
Adedoyin A; Bernardo JF; Swenson CE; Bolsack LE; Horwith G; DeWit S; Kelly E; Klasterksy J; Sculier JP; DeValeriola D; Anaissie E; Lopez-Berestein G; Llanos-Cuentas A; Boyle A; Branch RA
Antimicrob Agents Chemother; 1997 Oct; 41(10):2201-8. PubMed ID: 9333048
[TBL] [Abstract][Full Text] [Related]
14. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
15. Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma.
Ramaswamy M; Wallace TL; Cossum PA; Wasan KM
Antimicrob Agents Chemother; 1999 Jun; 43(6):1424-8. PubMed ID: 10348764
[TBL] [Abstract][Full Text] [Related]
16. The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu.
Wasan KM; Lopez-Berestein G
J Drug Target; 1994; 2(5):373-80. PubMed ID: 7704481
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
Yardley V; Croft SL
Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
[TBL] [Abstract][Full Text] [Related]
18. The in vitro plasma distribution of a novel cholesteryl ester transfer protein inhibitor, torcetrapib, is influenced by differences in plasma lipid concentrations.
Lee SD; Wasan KM; Calcagni A; Avery M; McCush F; Chen C
Pharm Res; 2006 May; 23(5):1025-30. PubMed ID: 16715393
[TBL] [Abstract][Full Text] [Related]
19. Analytical method development and comparability study for AmBisome® and generic Amphotericin B liposomal products.
Liu Y; Mei Z; Mei L; Tang J; Yuan W; Srinivasan S; Ackermann R; Schwendeman AS
Eur J Pharm Biopharm; 2020 Dec; 157():241-249. PubMed ID: 32980448
[TBL] [Abstract][Full Text] [Related]
20. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.
Wasan KM; Rosenblum MG; Cheung L; Lopez-Berestein G
Antimicrob Agents Chemother; 1994 Feb; 38(2):223-7. PubMed ID: 8192447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
